Mr. Wang Yao is the Clinical Trial Operations Director of the Group. He graduated from China Pharmaceutical University with a bachelor's degree in Pharmaceutics, and then obtained a master's degree in medicinal chemistry from Nanjing Medical University.
Mr. Wang has over 10 years of management experience in the pharmaceutical clinical CRO (CO-CRO Medical Development Co.,Ltd.), specialized in the optimization of clinical trial quality management systems, project management operations, and the supervision of clinical monitoring teams. He has participated in more than 50 clinical trials (Phases I to IV) for new drugs, covering multiple disease areas such as oncology, immunology, and infectious diseases. In addition, he has successfully conducted the clinical trials of several National Science and Technology Major Projects of the "12th Five-Year Plan" and "13th Five-Year Plan".
He has been responsible for the clinical trial and new drug application of five drugs. These include China's first long-acting anti-HIV drug. At the same time, he was responsible for the China's second approved anti-HIV drug (the first oral anti-HIV innovative drug). He also contributed to China’s first CDE-approved Chinese patent medicine for seasonal allergic rhinitis.